RefleXion Medical, Inc., headquartered in the United States, is a pioneering force in the field of radiation therapy, specialising in innovative cancer treatment solutions. Founded in 2009, the company has made significant strides in developing its unique biology-guided radiotherapy (BgRT) technology, which integrates real-time imaging to target tumours more effectively while minimising damage to surrounding healthy tissue. With a strong presence in major operational regions across North America, RefleXion is committed to transforming cancer care through its advanced treatment systems. The company’s flagship product, the RefleXion X1, stands out for its ability to adapt to patient movement, offering a personalised approach to radiation therapy. Recognised for its contributions to the oncology sector, RefleXion Medical continues to solidify its market position as a leader in innovative cancer treatment solutions.
How does RefleXion Medical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
RefleXion Medical, Inc.'s score of 23 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
RefleXion Medical, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that RefleXion Medical may not have established formal commitments to reduce carbon emissions or engage in climate initiatives at this time. As the industry increasingly prioritises sustainability, it will be essential for RefleXion Medical to consider developing and communicating its climate commitments to align with broader environmental goals.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
RefleXion Medical, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

